The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
This is multicenter, open-label, 2-part crossover study. Eligible subjects will have metastatic or unresectable solid tumors. This study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline. The treatment phase consists of Periods 1 and 2 (Part A), Treatment (Part B), and Follow-up.
Solid Tumor, Adult
DRUG: Oraxol
Comparison of the concentration-time profile of Oral Paclitaxel in plasma for 168 hours when taken with or without food., 24 months
Comparison of the concentration-time profile of HM30181 in plasma for 168 hours when taken with or without food., 24 months|The proportion of patients with tumor responses after the initiation of treatment., RECIST v1.1 criteria defined as complete response, partial response, stable disease or progressive disease, At baseline and every 8 weeks through study completion, approximately 24 months|Incidence of Adverse Events (Safety and Tolerability), Evaluate the safety of Oraxol. Number of participants with treatment-related adverse events., 24 months
This is multicenter, open-label, 2-part crossover study. Eligible subjects will have metastatic or unresectable solid tumors. This study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline. The treatment phase consists of Periods 1 and 2 (Part A), Treatment (Part B), and Follow-up.